No savings at 50? 2 FTSE 100 dividend stocks that could still help you retire in luxury

Are you approaching retirement with an empty wallet? Royston Wild explains how you can still get rich before the time you hang up your work apron.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pensioner poverty is something we all need to get increasingly serious about. Approximately one in 20 of retired Britons is now living close to, or beyond, the breadline. I know somebody who’s close to turning 50 with hardly any savings to fall back on.

My first piece advice to them, however, was don’t panic. It’s still possible for anyone in this position to make a sizeable nest egg in the 15-or-so years between now and the State Pension age of 65. You just need to be a bit more careful with how you use your spare cash. Time isn’t on your side, after all, so picking dependable earnings generators which offer big dividends today is essential.

Medical marvel

GlaxoSmithKline (LSE: GSK) is one Footsie share I expect to deliver exceptional shareholder returns over the next decade and a half as global demand for healthcare booms.

The patent expirations on key drugs that previously crushed earnings haven’t quite been put to bed, but investors can still look forward to solid profits growth at Glaxo as sales of its new medicines take off. During the first half, for example, the rapid growth of its recently-launched Trelegy and Nucala blockbuster brands pushed revenues at its Respiratory division 16% higher to £752m.

Its product pipeline is chock-full too, with 44 new medicines in development in fast-growing areas such as infectious diseases (including HIV), oncology and respiratory for investors to look forward to. And, judging from the steady flow of positive testing updates and regulatory approvals from across the globe, it seems as if the pharma giant’s back on the path of another golden era.

One last thing to celebrate. At current prices, Glaxo trades on a forward P/E ratio of 14.8 times and carries a big 4.6% corresponding dividend yield.

Home comforts

Another dependable, big dividend payer I reckon’s a top buy today for those approaching retirement is Taylor Wimpey (LSE: TW). It currently carries a forward P/E ratio of 7.9 times and a monster dividend yield of 11.2%, making it an irresistible buy (in my opinion at least) at today’s prices.

It’s possible the fallout of the Brexit saga could have significant negative effects for the UK economy through the next decade and thereafter, a situation that could keep property price growth hemmed in. But I’m confident the housebuilders can still thrive over the long term, given the country’s chronic homes shortage.

For decades now, government has failed to get a serious handle on the problem and there’s nothing to suggest anything is about to change. Indeed, recent Whitehall pledges to build 300,000 new homes per year by the mid-202s are already in tatters, thanks in part to the miles and miles of red tape still curtailing the creation of newbuild homes. What’s more, with ultra-low interest rates now the ‘new norm’, buyer affordability is likely to remain well-supported at least through the next decade, worsening that supply/demand imbalance still further.

Royston Wild owns shares of Taylor Wimpey. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Growth Shares

2 of the cheapest FTSE 100 stocks to consider buying as we hit 2026

Jon Smith calls out a couple of FTSE 100 companies that have fallen in the past year that he believes…

Read more »

Tesla building with tesla logo and two teslas in front
Investing Articles

Why Tesla stock outperformed the S&P 500 — again — in 2025

As the Tesla share price shrugs off declining revenues and profits to climb 19%, what kind of further excitement will…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Thinking of investing in the stock market? Keep these basic rules in mind

Investing in the stock market can put investors on the fast track to building wealth and earning passive income. And…

Read more »

piggy bank, searching with binoculars
US Stock

This Dow Jones stock could be a dark horse outperformer for 2026

Jon Smith looks across the pond and spots a Dow Jones company that has fallen by 11% in the past…

Read more »

Investing Articles

Why Greggs shares crashed 40% in 2025

Greggs has more stores than it had a year ago and total sales are higher, so is a 40% discount…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

4 pros and cons of buying Lloyds shares in 2026!

Investors piled into Lloyds shares last year as the bank delivered strong trading numbers in tough conditions. Could the FTSE…

Read more »

Investing Articles

Prediction: AI stocks will rise again in 2026 and Nvidia’s share price will soar to this level

Can Nvidia and other AI stocks continue to perform in 2026? Edward Sheldon believes so. Here, he explains why he’s…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

3 S&P 500 growth stocks that could make index funds looks silly over the next 5 years

Edward Sheldon believes these three high-flying S&P 500 stocks have the potential to smash the market over the next five…

Read more »